6-O-benzylguanine has been used in trials studying the treatment of HIV Infection, Adult Gliosarcoma, Adult Glioblastoma, Stage I Adult Hodgkin Lymphoma, and Stage II Adult Hodgkin Lymphoma, among others.
Henry Ford Hospital, Detroit, Michigan, United States
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
NCI - Neuro-Oncology Branch, Bethesda, Maryland, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Children's National Medical Center, Washington, District of Columbia, United States
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Henry Ford Hospital, Detroit, Michigan, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
Simmons Cancer Center - Dallas, Dallas, Texas, United States
Indiana University Cancer Center, Indianapolis, Indiana, United States
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
Evanston Northwestern Health Care, Evanston, Illinois, United States
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Case Western Reserve University, Cleveland, Ohio, United States
Pediatric Brain Tumor Consortium, Memphis, Tennessee, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.